1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. 89bio, Inc.
  6. Notizie
  7. Altre lingue
    ETNB   US2825591033

89BIO, INC.

(ETNB)
  Rapporto
Tempo differito Nasdaq  -  22:00 29/06/2022
3.450 USD   -2.82%
29/0689BIO, INC.: da BTIG è Buy
MM
29/0689bio ha un prezzo maggiorato per un'offerta pubblica di 94,5 milioni di dollari
MT
28/0689bio, Inc. riporta i risultati positivi dello studio di fase 2 ENTRIGUE di Pegozafermin nei pazienti con grave ipertrigliceridemia (SHTG)
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su 89BIO, INC.
29/0689bio Prices Upsized $94.5 Million Public Offering
29/0689bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock,..
28/0689bio Launches $75 Million Offering of Shares, Warrants; Sees Positive Results for Phas..
28/0689BIO: Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Pa..
28/0689BIO, INC.: Other Events (form 8-K)
28/0689bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded..
28/0689bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in P..
28/0689bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermi..
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2500 Value Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Dynamic Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Value Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell Small Cap Comp Value Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2500 Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000E Value Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000E Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000 Value Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000 Index
24/0689BIO, INC.(NASDAQGM: ETNB) dropped from Russell Small Cap Completeness Index
21/0689bio to Present Additional Pegozafermin Data at EASL International Liver Congress&trad..
20/0689BIO, INC.(NASDAQGM: ETNB) dropped from S&P Global BMI Index
07/0689BIO, INC.: Submission of Matters to a Vote of Security Holders (form 8-K)
12/0589BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of..
11/0589BIO, INC.: Results of Operations and Financial Condition (form 8-K)
11/0589bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
11/0589bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
11/0589bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
03/0589bio to Participate in Upcoming Investor Conferences
26/0489bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
25/03SECTOR UPDATE: Health Care Stock Edging Higher Near Friday Close
25/03SECTOR UPDATE: Health Care Stocks Weakening in Afternoon Trading
24/0389BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of..
24/0389bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
24/0389BIO: Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate..
24/0389BIO, INC.: Results of Operations and Financial Condition (form 8-K)
24/0389bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
24/0389bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporat..
14/03Spruce Biosciences Names New Chief Medical Officer
04/0389BIO: Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors - Fo..
04/0389BIO, INC. Change in Directors or Principal Officers (form 8-K/A)
24/0289BIO: Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors - Fo..
24/0289BIO, INC.: Change in Directors or Principal Officers (form 8-K)
24/0289bio, Inc. Appoints Edward Morrow Atkinson to the Board
24/0289bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
09/0289bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Confer..
24/0189BIO: Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial..
24/0189BIO, INC.: Other Events (form 8-K)
24/0189bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Tria..
24/0189Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 2..
202189BIO, INC.(NASDAQGM: ETNB) added to NASDAQ Biotechnology Index
202189bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Vo..
202189bio, Inc. Presents New Data from Phase 1B/2A Nash Study Showing Bio89-100 Reduces Spl..
202189BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of..
202189bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form..
202189BIO, INC.: Results of Operations and Financial Condition (form 8-K)
202189bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
202189bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
202189bio Announces Appointment of Kathy LaPorte to its Board of Directors - Form 8-K
202189BIO, INC.: Change in Directors or Principal Officers, Financial Statements and Exhibits..
202189bio Announces Appointment of Kathy LaPorte to its Board of Directors
202189bio Announces Appointment of Kathy Laporte to Its Board of Directors
202189BIO: to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's Th..
2021INSIDER SELL: 89bio
202189BIO: to Participate in the Cantor Global Healthcare Conference
2021INSIDER SELL: 89bio
202189BIO, INC.(NASDAQGM: ETNB) added to S&P Global BMI Index
202189bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
202189BIO: Management's Discussion and Analysis of Financial Condition and Results of Operati..
202189BIO: Reports Second Quarter 2021 Financial Results and Provides Corporate Update (Form ..
202189BIO, INC.: Results of Operations and Financial Condition (form 8-K)
202189Bio, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and..
202189BIO: Reports Second Quarter 2021 Financial Results and Provides Corporate Update
202189BIO: to Participate in Upcoming Investor Conferences
202189BIO: Completes Target Enrollment in Histology Cohort to Evaluate Fatty Liver Disease Tr..
202189BIO: Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Trea..
1  2  3Succ.